Cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
=== Sabbatical leave (1913/1914) === In 1913/1914 Robertson took 12 months sabbatical leave from the University of California. He spent four months in Adelaide, during which time he delivered two lectures: "Some Factors in the Cell Growth of Tumors [sic]", to the Microscopical Society of South Australia on 22 July 1913, and "Some Economic Aspects of Scientific Research", to the Science Association of the Adelaide University on 6 August 1913. On 12 November 1913, he submitted a 17-page report, Report on the Scope and Administration of an Institute for Scientific Research in Australia (BR.13), to the South Australian branch of the British Science Guild. The Guild's Report, with Robertson's report appended to it, was immediately given to Patrick "Paddy" McMahon Glynn, the Member for Angas, and Minister for Foreign Affairs, for him to directly hand it on to the Prime Minister, Joseph Cook. According to George Currie and John Graham (GC.1, pp.8–9), there is no evidence that Robertson's (1913) report ever reached the Prime Minister (or any other Minister) at that time. Robertson then travelled widely throughout Europe. In March 1914 he met up with Ivan Pavlov in Russia, and Pavlov gave him a personal tour of his laboratories at the Institute of Experimental Medicine in Saint Petersburg.
The OSA frequency increase with age for the women, and is in particular linked to the onset of menopause and associated hormonal changes. The mortality is higher for women. If studied carefully in a sleep lab by polysomnography (formal "sleep study"), it is believed that approximately 1 in 5 American adults would have at least mild OSA. In the US, some studies report that it is more frequent among the Hispanic and African American population than among the white population.
The rectus abdominis, (Latin: straight abdominal) also known as the "abdominal muscle" or simply better known as the "abs", and sometimes informally referred to as the "six-pack", is a pair of segmented skeletal muscle on the ventral aspect of a person's abdomen. The paired muscle is separated at the midline by a band of dense connective tissue called the linea alba, and the connective tissue defining each lateral margin of the rectus abdominus is the linea semilunaris. The muscle extends from the pubic symphysis, pubic crest and pubic tubercle inferiorly, to the xiphoid process and costal cartilages of the 5th–7th ribs superiorly. The rectus abdominis muscle is contained in the rectus sheath, which consists of the aponeuroses of the lateral abdominal muscles. Each rectus abdominus is traversed by bands of connective tissue called the tendinous intersections, which interrupt it into distinct muscle bellies.
Sources: en.wikipedia.org
Forensic chemists' analysis can provide leads for investigators, and they can confirm or refute their suspicions. The identification of the various substances found at the scene can tell investigators what to look for during their search. During fire investigations, forensic chemists can determine if an accelerant such as gasoline or kerosene was used; if so, this suggests that the fire was intentionally set. Forensic chemists can also narrow down the suspect list to people who would have access to the substance used in a crime. For example, in explosive investigations, the identification of RDX or C-4 would indicate a military connection as those substances are military grade explosives. On the other hand, the identification of TNT would create a wider suspect list, since it is used by demolition companies as well as in the military. During poisoning investigations, the detection of specific poisons can give detectives an idea of what to look for when they are interviewing potential suspects. For example, an investigation that involves ricin would tell investigators to look for ricin's precursors, the seeds of the castor oil plant. Forensic chemists also help to confirm or refute investigators' suspicions in drug or alcohol cases. The instruments used by forensic chemists can detect minute quantities, and accurate measurement can be important in crimes such as driving under the influence as there are specific blood alcohol content cutoffs where penalties begin or increase.
The protein count and GC content of the strains of the P. fluorescens group ranged between 4152 and 6678 (average: 5603) and between 58.7–62% (average: 60.3%), respectively. Another comparative genomic analysis of 93 P. fluorescens genomes identified eight major subgroups and developed a set of nine genes as markers for classification within this lineage. A recent comparative genomic analysis of the P. fluorescens complex has further increased the number of major subgroups to 11.
=== Effects on sugar absorption and insulin secretion === Gymnemic acid compounds in Gymnema sylvestre can also attach to receptors on the intestinal walls, helping to reduce absorption of sugar molecules in the gut. This process can lower blood sugar and promote insulin secretion and release. However, its antidiabetic properties were not confirmed in rats.
Sources: en.wikipedia.org
AOA1 is caused by biallelic mutation in APTX gene. Missense mutations (mutations that result in the change of amino acids in the specific location of the protein) usually result in much milder symptoms and delayed onset than truncating mutations. Founder effect was found in Japanese and Portuguese patients (V230fs and P206L are Japanese founder mutations; R199H and W279X are Portuguese founder mutations). Monoallelic variants, in rare cases, can produce phenotype similar to multiple system atrophy.
The legion was probably founded by Diocletian to help defend the Danube. I Pontica: the legion was founded by Dioceltian to help defend Pontus Polemoniacus. The legion was stationed in Trapezus. Legio II II Armeniaca II Britannica: comitatensis under Magister Peditum II Flavia Constantia: comitatensis under the command of the Magister Peditum II Flavia Virtutis: comitatensis under the command of the Magister Peditum II Herculia (devoted to Hercules): levied by Diocletian, stationed in Scythia Minor II Isaura II Iulia Alpina: pseudocomitatensis under the command of the Magister Peditum, in Comes Illyricum command. It was probably founded by Crispus or Constans. Its objective was to defend Alpes Cottiae II Felix Valentis Thebaeorum: comitatensis Legio III III Diocletiana III Flavia Salutis: comitatensis unit of the Late Roman Empire under the command of the Magister Militum in the west. The Legio III Flavia Salutis was raised by either Constantius II or Diocletian and was used to guard North Africa. III Herculea: comitatensis under the command of the Comes Illyricum III Isaura III Iulia Alpina: comitatensis under the command of the Magister Peditum command in Italy Legio IV IV Italica IV Martia IV Parthica Legio V V Iovia (maybe the Jovians) V Parthica Legio VI VI Gemella VI Gallicana VI Herculia (maybe the Herculians) VI Hispana VI Parthica Legio XII XII Victrix
=== Fortification === According to the Global Fortification Data Exchange, vitamin K deficiency is so rare that no countries require that foods be fortified. The World Health Organization does not have recommendations on vitamin K fortification.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.